Get started
Author

Yan Xing

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification
2022 · Siqing Fu, Shuyang Yao, et al. · Journal of Clinical Oncology · 100
PDF
Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy
2023 · Tiantian Zhang, Tony Hong-Ting Jou, et al. · Journal of Clinical Medicine · 82
PDF
Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive Review
2024 · Abdulaziz Shebrain, Omer A. Idris, et al. · Journal of Clinical Medicine · 19
PDF
The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function
2023 · Karen Tsai, Huiyan Ma, et al. · Thyroid · 18
PDF
Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus
2023 · Robin Hilder, Karen Tsai, et al. · Frontiers in Endocrinology · 10
A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.
2022 · Brian Gastman, Steven Fling, et al. · Journal of Clinical Oncology · 6
Association of Claudin18.2 expression, PD-L1, and prognostic implications in gastric and gastroesophageal junction cancers.
2025 · Dani Ran Castillo, Mengni Guo, et al. · Journal of Clinical Oncology · 3
PDF
Combined Regional Approach of Talimogene laherparepvec and Radiotherapy in the Treatment of Advanced Melanoma
2024 · Andrew Tam, Colton Ladbury, et al. · Cancers · 3
A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors
2022 · Amita Patnaik, Erika Hamilton, et al. · Cancers · 2
PDF
Early‐Onset Gastric Cancer as a High‐Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes
2026 · Dani R. Castillo, Pranati Shah, et al. · Cancer Medicine
Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform
2026 · Tithi Ghosh Halder, Erin Kelley, et al. · OncoImmunology
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma
2026 · Elena Garralda, Patrick Schöffski, et al. · European Journal of Cancer
Real-world outcomes of lifileucel in advanced melanoma: A single-institution experience.
2026 · Kelly Mahuron, Alexander Go, et al. · Journal of Clinical Oncology
The early-onset paradox of gastric cancer: Assessment of geographic clustering, biology, treatment, and outcomes.
2026 · Pranati Dharmesh Shah, Dani Ran Castillo, et al. · Journal of Clinical Oncology
Treatment trends and survival outcomes in clinical stage III melanoma: A real-world analysis of NCDB data (2006-2022).
2025 · Daniel Park, Dani Ran Castillo, et al. · Journal of Clinical Oncology
Preclinical Proof of Concept for a personalized SNAP TM -TIL (Specific Neo-Antigen Peptides -TIL) therapy platform
2024 · Tithi Ghosh Halder, Erin Kelley, et al. · bioRxiv (Cold Spring Harbor Laboratory)
717 Interim clinical update of the phase 1b trial of ATRC-101 as monotherapy or in combination with pembrolizumab for select advanced solid tumors
2022 · Bartosz Chmielowski, John Weroha, et al. · Regular and Young Investigator Award Abstracts
PDF
Current Therapeutics and Future Perspectives for Treatment of Advanced BRAF V600 mutant Melanoma
2022 · Yan Xing · Novel Approaches in Cancer Study
PDF
Works count: 18
Citation count: 242
H-index: 6
I10-index: 5
Year
Topic
Type